ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

ADMA Biologics, Inc.NASDAQ: ADMA

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares declines year over year

Q2 FY2026 weighted avg shares of 228.23M shares fell 5.5% year over year, behind the -1.0% change in trailing-twelve-month weighted avg shares. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -5.5% toward the trailing-twelve-month pace of -1.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
228.23M-3.3% QoQ
Last fiscal yearDec 2025
238.3M+2.2% YoY
LTMJun 2026
235.22M-1.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5.5%——
1 year+2.2%——
3-year CAGR+6.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
238.3M USD
Year-over-year change
+2.2%
4-year CAGR
+14.3%

Weighted Avg Shares vs competitors

How ADMA compares with its peers on the latest reported figures

  • ADMA's LTM Jun 2026 weighted avg shares of 235.22M shares is the 2nd highest of the 4 companies compared; the peer median is 193.02M shares.
  • Its year-over-year change of -1.0% is the lowest of 4, against a peer median of +2.0%.
  • Over three fiscal years its annual growth of +6.4% compares with a peer median of +8.3%.
ADMA Competitors Peer median
Weighted Avg Shares for ADMA and competitors
Company Period LTM YoY 3-year CAGR
GRFSGrifols, S.A.LTM Jun 2026680.56M -0.2%+0.0%
ADMAADMA Biologics, Inc.LTM Jun 2026235.22M -1.0%+6.4%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
ABUSArbutus Biopharma CorporationLTM Mar 2026192.17M +2.0%+8.3%
Peer median (excluding ADMA) 193.02M+2.0%+8.3%

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.